Standout Papers
- Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy (2019)
- Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial (2021)
Immediate Impact
3 by Nobel laureates 5 from Science/Nature 66 standout
Citing Papers
Advances in diagnosis and treatment of bladder cancer
2024 Standout
Natural killer cell therapies
2024 StandoutNature
Works of Bradley A. McGregor being referenced
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
2021 Standout
Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features
2019
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Bradley A. McGregor | 1344 | 1698 | 1117 | 168 | 3.0k | |
| J.L. González-Larriba | 1756 | 1942 | 697 | 146 | 3.2k | |
| Mehmet Asım Bilen | 1478 | 1976 | 1018 | 306 | 3.9k | |
| André P. Fay | 1353 | 1252 | 740 | 112 | 2.4k | |
| Alessia Cimadamore | 1267 | 856 | 787 | 143 | 2.5k | |
| Pablo Maroto | 1746 | 1505 | 1605 | 162 | 3.8k | |
| Roberto Petrioli | 1209 | 1594 | 834 | 135 | 3.0k | |
| Thomas Powles | 1051 | 2338 | 1872 | 103 | 3.5k | |
| Aristotle Bamias | 769 | 1845 | 832 | 86 | 3.2k | |
| Terence W. Friedlander | 827 | 1803 | 1136 | 109 | 2.9k | |
| F. Cognetti | 1318 | 2254 | 1889 | 128 | 4.7k |
All Works
Login with ORCID to disown or claim papers
Loading papers...